Investing.com -- Veracyte Inc (NASDAQ:VCYT)股价上涨7.6%，此前该公司宣布将于2025年7月29日（星期二）市场开盘前被纳入标普小型股600指数。
这家诊断测试制造商将取代Triumph Group Inc (NYSE:TGI)在小型股基准指数中的位置，因为Triumph正被Warburg Pincus LLC和Berkshire Partners LLC收购。该收购预计将在满足最终交割条件后不久完成。
指数成分股的调整通常会推动股价上涨，因为追踪该基准指数的基金需要购买新增公司的股票。Veracyte被纳入标普小型股600指数对这家医疗保健公司来说是一个重要里程碑，有可能提高其在投资者中的知名度。
这一指数变更将于7月29日市场开盘前生效，Veracyte将加入指数的医疗保健板块，而Triumph Group将退出工业板块。
Veracyte专注于基因组诊断，开发和商业化帮助医生提高诊断准确性并优化患者护理的测试。
本文由人工智能协助翻译。更多信息，请参见我们的使用条款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.